News
XCUR
0.5090
-1.17%
-0.0060
EXICURE, INC. RECEIVED NASDAQ DELINQUENCY NOTICE ON LATE FILING OF ITS FORM 10-K
Reuters · 3d ago
Weekly Report: what happened at XCUR last week (0415-0419)?
Weekly Report · 3d ago
Weekly Report: what happened at XCUR last week (0408-0412)?
Weekly Report · 04/15 11:40
Weekly Report: what happened at XCUR last week (0401-0405)?
Weekly Report · 04/08 11:46
EXICURE FILES FOR NON-TIMELY 10-K - SEC FILING
Reuters · 04/01 20:25
Weekly Report: what happened at XCUR last week (0325-0329)?
Weekly Report · 04/01 11:42
Weekly Report: what happened at XCUR last week (0318-0322)?
Weekly Report · 03/25 11:46
Weekly Report: what happened at XCUR last week (0311-0315)?
Weekly Report · 03/18 11:44
Weekly Report: what happened at XCUR last week (0304-0308)?
Weekly Report · 03/11 11:40
12 Health Care Stocks Moving In Thursday's Pre-Market Session
NKGen Biotech (NASDAQ:NKGN) stock rose 18.0% to $2.16 during Thursday's pre-market session. The company's market cap stands at $47.2 million. Nutex Health stock increased by 15.32% and Avinger stock moved upwards by 13.51%. Avid Bioservices stock declined by 37.4% during the pre- market session.
Benzinga · 03/07 13:06
Weekly Report: what happened at XCUR last week (0226-0301)?
Weekly Report · 03/04 11:44
5 Value Stocks In The Healthcare Sector
A value stock traditionally has a lower price when compared to companies in the same industry. A low price-to-earnings multiple is a good indication that the company is undervalued. Benzinga Insights has selected five notable value stocks in the healthcare sector. The value stocks were selected based on quantified analysis.
Benzinga · 02/26 14:44
Weekly Report: what happened at XCUR last week (0219-0223)?
Weekly Report · 02/26 12:00
5 Value Stocks In The Healthcare Sector
What is a value stock? A value stock is traditionally defined in terms of how investors are valuing a company's future growth prospects. Spok Holdings has a low P/E multiples and is considered to be a notable value stock in the healthcare sector. The company's most recent dividend yield sits at 8.6%.
Benzinga · 02/19 14:42
Weekly Report: what happened at XCUR last week (0212-0216)?
Weekly Report · 02/19 12:02
Weekly Report: what happened at XCUR last week (0205-0209)?
Weekly Report · 02/12 11:49
12 Health Care Stocks Moving In Thursday's Pre-Market Session
China SXT Pharmaceuticals (NASDAQ:SXTC) stock rose 122.5% to $4.05 during Thursday's pre-market session. The company's market cap rose to $2.2 million. Titan Pharma, Mineralys Therapeutics and Nutex Health were among the gainers. Jin Medical International shares decreased by 93.9% during the session.
Benzinga · 02/08 13:05
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Societal CDMO (NASDAQ:SCTL) shares moved upwards by 23.4% to $0.57 during Wednesday's pre-market session. Elicio Therapeutics and PepGen also moved upwards. Apollomics shares rose by 19.86% during the session. Losers CytoMed Therapeutic and GRI Bio stock declined by 16.9%.
Benzinga · 02/07 13:06
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Sharps Technology (NASDAQ:STSS) stock increased by 27.9% to $0.37 during Tuesday's after-market session. DMK Pharmaceuticals (NASdaq:DMK) stock moved upwards by 22.84%. The company's market cap stands at $5.6 million. Vicarious Surgical shares increased by 5.4%.
Benzinga · 02/06 21:31
Why FMC Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
FMC Corporation shares dipped 9.8% to $54.51 after the company reported worse-than-expected fourth-quarter results. InVivo Therapeutics Holdings Corp. Shares jumped 144.4% after dipping around 26% on Monday. Spotify Technology S.A. Also rose in today's mid-day session.
Benzinga · 02/06 18:17
More
Webull provides a variety of real-time XCUR stock news. You can receive the latest news about Exicure Inc through multiple platforms. This information may help you make smarter investment decisions.
About XCUR
Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company is developing nucleic acid therapies targeting ribonucleic acid (RNA) to address both genetic and non-genetic neurological disorders. Its lead program is a non-opioid pain analgesic directed against the genetically validated target SCN9A. It is engaged in discovery efforts across a range of indications and therapeutic targets, such as pain using non-opioid analgesics, as well as rare neurological genetic disorders, including Huntington's disease, Angelman Syndrome, Batten disease, spinocerebellar ataxia, and sporadic amyotrophic lateral sclerosis (ALS). The Company focuses on pursuing out-licensing opportunities for its clinical asset, cavrotolimod, as well as for its preclinical candidates, including the SCN9A program for neuropathic pain.